by Imagenetix on November 22, 2005
SAN DIEGO–(BUSINESS WIRE)–Nov. 22, 2005–Imagenetix, Inc. (OTCBB:IAGX – News), an innovator of scientifically tested, natural-based, proprietary bioceutical products that enhance human health, today announced that, for the second fiscal quarter ended September 30, 2005, it reported revenue of $2,016,295, a 95 percent increase on revenues of $1,034,146 reported in the same quarter of the prior [...]
by Imagenetix on November 16, 2005
SAN DIEGO–(BUSINESS WIRE)–Nov. 16, 2005–Imagenetix, Inc. (OTCBB:IAGX – News), an innovator of scientifically tested, natural-based, proprietary bioceutical products that enhance human health, today announced it has signed a license agreement with the University of Minnesota for the exclusive rights to the University’s recently awarded patent covering a natural compound for lowering the body’s levels of [...]
by Imagenetix on September 27, 2005
SAN DIEGO–(BUSINESS WIRE)–Sept. 27, 2005–Imagenetix, Inc. (OTCBB:IAGX – News), www.imagenetix.net a company focused on inflammation and inflammation related markets, today announced the appointment of Jeffrey G. McGonegal to the Imagenetix Board of Directors and his appointment as Chairman of the Audit Committee and the Audit Committee’s Financial Expert.
In 1974, Mr. McGonegal began his career as [...]
by Imagenetix on September 26, 2005
SAN DIEGO–(BUSINESS WIRE)–Sept. 26, 2005–Imagenetix, Inc. (OTCBB:IAGX – News), www.imagenetix.net, a company focused on inflammation and inflammation-related markets, today announced Bob Burg has joined Imagenetix’s Board of Directors.
Owner of The Burg Group, Mr. Burg’s 25 years of business experience have focused on sales and marketing campaigns, channel distribution, and product sourcing. Mr. Burg has extensive [...]
by Imagenetix on August 16, 2005
Sales Hit All Time High – Up 142%. Before-Tax Income Soars 174%. Company Reports Ten Consecutive Quarters of Operating Profits
San Diego, CA – August 16, 2005 – Imagenetix, Inc. (Symbol: IAGX), www.imagenetix.net, a company focused on inflammation and inflammation related markets, announces the results for the first fiscal quarter ended June 30, 2005. For the [...]